|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of medical therapies on inflammatory bowel disease complication rate显示文摘Crohn's disease and ulcerative colitis are progressive diseases associated with a high risk of complications over time including strictures,fistulae,perianal complications,surgery,and colorectal cancer.Changing the natural history and avoiding evolution to a disabling disease should be the main goal of treatment.In recent studies,mucosal healing has been associated with longer-term remission and fewer complications.Conventional therapies with immunosuppressive drugs are able to induce mucosal healing in a minority of cases but their impact on disease progression appears modest.Higher rates of mucosal healing can be achieved with anti-tumor necrosis factor therapies that reduce the risk of relapse,surgery and hospitalization,and are associated with perianal fistulae closure.These drugs might be able to change the natural history of the disease mainly when introduced early in the course of the disease.Treatment strategy in inflammatory bowel diseases should thus be tailored according to the risk that each patient could develop disabling disease. | Catherine Reenaers Jacques Belaiche Edouard Louis | 2012 | World Journal of Gastroenterology2012，18，29： | 4 |
| 2 | Increased expression of receptor activator of NF-kappaB ligand (RANKL) , its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients 显示文摘 | Franchimont N Reenaers C Lambert C | | Clinical & Experimental \ Immunology0，138，3： | 1 |
| 3 | Role of endos- copy,cross-sectional imaging and biomarkers in CrohnPs disease monitoring显示文摘 | Benitez JM Meuwis MA Reenaers C | 2013 | Gut2013，62，12： | 1 |
| 4 | A patient who survived total colonic ulcerative colitis surinfected by cytomegalovirus complicated by toxic megacolon and disseminated intravascular coagulation显示文摘 | Laurent S Reenaers C Detroz B | 2005 | Acta Gastroenterol Belg2005，68，2： | 1 |
| 5 | Do clinical factors help to predict disease course in inflammatory bowel disease?显示文摘While therapeutic strategies able to change the natural history of the disease are developing,it is of major importance to have available predictive factors for aggressive disease to try and target these therapeutic strategies.Clinical predictors have probably been the most broadly studied.In both Crohn's disease(CD) and ulcerative colitis(UC),age at diagnosis,disease location and smoking habit are currently the strongest predictors of disease course.A younger age at onset is associated with more aggressive disease both in CD and UC.Disease location in CD is associated with different types of complications:surgery and recurrence in upper gastrointestinal and proximal small bowel disease;and surgery in distal small bowel disease and peri-anal lesions in rectal disease.In UC,extensive colitis is clearly been associated with more severe disease.Finally,active smoking globally increases disease severity in CD but decreases it in UC.Besides these important factors,others may predispose to some specific disease evolution and complications,and are also reviewed in the present paper. | Edouard Louis Jacques Belaiche Catherine Reenaers | 2010 | World Journal of Gastroenterology2010，16，21： | 1 |
| 6 | Current directions of biologic thera- pies in inflammatory bowel disease 显示文摘 | Reenaers C Louis E Belaiche J | 2010 | Therap Adv Gastroenterol2010，3，： | 1 |
| 7 | Genetics of ulcerative colitis:The come - back of interleukin 10 显示文摘 | Louis E Libioulle C Reenaers C | 2009 | Gut2009，58，9： | 1 |
| 8 | Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring显示文摘 | Jose-Manuel Benitez Marie-Alice Meuwis Catherine Reenaers Catherine Van Kemseke Paul Meunier Edouard Louis | 2013 | Gut2013，，12： | 1 |
| 9 | Increased expression of receptor activator of NF-kappa B ligand(RANKL),its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients显示文摘 | Franchimont N Reenaers C Lambert C | 2004 | Clin Exp Immunol2004，138，3： | 1 |
| 10 | Are we giving biologics too much time? When should we stop treatment?显示文摘The optimal duration of biological treatment, particu- larly anti-TNF, in inflammatory bowel disease (IBD) is a very important question both for patients and physicians. There is no published evidence to clearly and definitely answer this question. However data on natural history of IBD, long term safety of biologics, immunosuppressors (IS) cessation and some preliminary studies on biologics cessation may help us to discuss this topic. The decision to stop a biological treatment is currently based on a compromise between the benefits and risks associated with the prolongation of this treat- ment. IBD, more particularly CD, are characterized by the development of complications and the need for recurrent hospitalizations and surgeries in approximately 2/3 of cases. In these patients potentially in need of biological treatments, it is probable that, as it has been demonstrated for IS, the longer a stable remission has be achieved under treatment, the lower the risk of relapse is after treatment cessation. Further prospective studies should now aim at disclosing patient characteristics associated with a low risk of relapse to implement this strategy. | Edouard Louis J Belaiche C Reenaers | 2008 | World Journal of Gastroenterology2008，14，36： | 1 |
| 11 | Increased expression of receptor activator of NF-kappaB ligand (RANKL) , its receptor RANK and its decoy receptor osteoprote-gerin in the colon of crohnps disease patients显示文摘 | Franchimont N Reenaers C Lambert C | 2004 | Clin Exp Immunol2004，138，3： | 1 |
| 12 | 比利时南部基因5型丙型肝炎病毒患者:流行病学特征和治疗应答显示文摘Data are scarce on patients infected with hepatitis C virus of genotype 5, due to the low prevalence of this genotype around the world. To better define the characteristics of these patients, we reviewed the files of 16 genotype 5 patients. Mean age was 38 ± 14. All patients were of European origin. Most of them (75% ) had been contaminated by transfusion within a short time period (between 1980 and 1991). There were no intravenous drug addicts. Seven patients received treatment. One patient did not respond to interferon (IFN) monotherapy. Of four patients treated with IFN and ribavirin, three became sustained viral responders. Two patients treated with pegylated IFN and ribavirin became sustained viral responders. In our region, genotype 5 patients seem to have been contaminated within a relatively short time period. Treatment with IFN or pegylated IFN and ribavirin gave a high rate (83% ) of sustained viral responses. | Delwaide J. Gerard C. Reenaers C. 李宏宇 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员